Cost-Effectiveness of Adding Rituximab to Splenectomy and Romiplostim for Treating Steroid-Resistant Idiopathic Thrombocytopenic Purpura in Adults
BMC Health Services Research - United Kingdom
doi 10.1186/s12913-015-0681-y
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 22, 2015
Authors
Publisher
Springer Science and Business Media LLC